Accessibility StatementSkip Navigation BETHESDA, Md., Nov. 20, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has engaged a construction firm to carry out the construction of the first Grade C manufacturing suite in the Company's Sawston, UK facility, the construction firm is onsite and the construction activities have begun. The Company anticipates tha ...

ROSEN, LEADING INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 20, 2025 2:11 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Pe ...

New York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026.SO WHAT: If you purchased Skye securities during the C ...

Key Takeaways VKTX finished enrollment of about 4,650 adults in the phase III VANQUISH-1 study of obesity drug VK2735.The study tests three weekly SC doses versus placebo, tracking body-weight change after 78 weeks.Rapid recruitment follows earlier full enrollment of the phase II VENTURE-Oral Dosing study this year.Viking Therapeutics (VKTX) announced that it has completed enrolling study participants in the phase III VANQUISH-1 study, which is evaluating the safety and efficacy of the subcutaneous (SC) for ...

PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.November 20, 2025 12:26 PM EST | Source: PreveCeutical Medical Inc.Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 20 ...

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has strategic partnerships with industry leaders, enhancing its research and development capabilities [1] Price Target Changes - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00, indicating a shift in analyst sentiment [2][5] - This decline in price target suggests potential influences from recent developments or broader market conditions affecting the biotech sector [2] Investment Considerations - Investors should monitor NovaBridge's ongoing clinical trials and strategic partnerships, as these factors could significantly impact future performance and stock valuation [3][5] - New announcements or updates from NovaBridge may provide further insights into potential stock movements [3] Comparative Analysis - In contrast, IMab has received a positive outlook from analysts, with a price target set at $8, reflecting increased optimism about its earnings prospects [4] - This comparison highlights the importance of analyst ratings and price targets in assessing biotech stocks [4][5]

Design Therapeutics (DSGN) added ~15% on Thursday after RBC Capital Markets upgraded the stock to Outperform from Sector Perform, citing a catalyst-rich period for the small molecule drug developer in the near-term. The upgrade comes after the Carlsbad, California-based Design ( ...

Accessibility StatementSkip Navigation DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple sys ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether uniQure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining th ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. Also from this source On this news, Regencell's stock price fell $3.09 per share, or 18.56%, to close at $13.56 per share on November 3, 2025. Pomerantz LLP, with offices in New ...